Autolus Therapeutics plc ADR (NASDAQ: AUTL) kicked off on Monday, down -5.42% from the previous trading day, before settling in for the closing price of $2.03. Over the past 52 weeks, AUTL has traded in a range of $1.99-$7.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 190.29%. While this was happening, its average annual earnings per share was recorded 24.89%. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
Considering the fact that the conglomerate employs 463 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 11.06%, while institutional ownership is 56.40%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.23% during the next five years compared to 3.32% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Take a look at Autolus Therapeutics plc ADR’s (AUTL) current performance indicators. Last quarter, stock had a quick ratio of 13.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Compared to the last year’s volume of 1.15 million, its volume of 1.33 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 9.57%. Additionally, its Average True Range was 0.14.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 0.65%, which indicates a significant decrease from 3.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.01% in the past 14 days, which was lower than the 70.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.47, while its 200-day Moving Average is $3.58. Nevertheless, the first resistance level for the watch stands at $2.01 in the near term. At $2.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.16. If the price goes on to break the first support level at $1.86, it is likely to go to the next support level at $1.81. Should the price break the second support level, the third support level stands at $1.71.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
The company with the Market Capitalisation of 510.95 million has total of 266,094K Shares Outstanding. Its annual sales at the moment are 1,700 K in contrast with the sum of -208,380 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -58,270 K.
